News Biogen buys CNS delivery specialist Alcyone Therapeutics Biogen buys Alcyone, bringing a partnered technology for delivery of antisense drugs into the central nervous system in-house.
News Lila Sciences' $235m first round, and other biofinancings Recent biotech financings include big rounds for Lila Sciences, Odyssey, and Ollin, with ARTHEx, Dualitas, and YolTech also in on the action.
News UK specialists call for more testing on psychedelics UK psychiatrists have called for a relaxation of restrictive rules on testing psychedelics, which are holding back research and clinical use.
News Regeneron drug on track to be second FOP treatment There is only one approved drug for ultra-rare disease FOP on the market, but Regeneron is hoping to add a second.
News Oral GLP-1 contest ramps up with new Novo Nordisk data Novo Nordisk has trumpeted data showing oral Wegovy matched the injectable version in a phase 3 trial, ramping up pressure on rival Eli Lilly.
News Roche poised to buy MASH drug developer 89bio for $3.5bn Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its phase 3 candidate pegozafermin for MASH.
Oncology ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o... For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
